Anup Kumar Trikannad

This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.

Assistant Professor

UAMS

Also affiliated: University of Arkansas Medical Center (2025–2026); Union Hospital (2022)

3 h-index 27 pubs 59 cited

Research Areas

Biomedical Subjects

OverviewAI-generated summary

Anup Kumar Trikannad's research focuses on understanding and improving outcomes for patients with multiple myeloma, particularly concerning infection prevention and treatment response. His work investigates the role of intravenous immunoglobulin (IVIG) supplementation in reducing infections in patients undergoing therapies such as BCMA-directed bispecific antibody and teclistamab therapy. Trikannad also explores T cell subsets as predictors of response to BCMA-targeting bispecific antibody therapy and examines the prognostic impact of lymphocyte kinetics and immune composition during these treatments.

His publications also address broader aspects of cancer care, including the stem cell origin of cancer and its clinical implications beyond immunotherapy. Trikannad has contributed to reviews on immunotherapy in bladder cancer and the staging dilemmas in oncology patients related to mediastinal lymphadenopathy after COVID-19 vaccination. He collaborates with researchers at the University of Arkansas for Medical Sciences, including César Sánchez, Hira Imad Cheema, J. Curran Henson, and Ankur Varma.

Metrics

h-index: 3
Publications: 27
Citations: 59

Positions

Assistant Professor publications 2024–2026

University of Arkansas for Medical Sciences Institution web page

Selected Publications

Immunotherapy role in bladder cancer treatment: a review of literature (2026)

Frontiers in Oncology DOI OpenAlex
Prognostic impact of lymphocyte kinetics and immune composition during bispecific antibody therapy in relapsed/refractory multiple myeloma (2026)

Blood Cancer Journal DOI OpenAlex
Acute Kidney Injury in Recipients of Chimeric Antigen Receptor T-Cell therapy: Clinical Characteristics and Impact on Mortality (2026)

Transplantation and Cellular Therapy DOI OpenAlex
Racial Differences in Outcomes Among Patients with Multiple Myeloma Treated at a Myeloma Center of Excellence: A Retrospective Cohort Study (2026)

Cancer Investigation DOI OpenAlex
The prognostic impact of lymphocyte counts and immune composition in bispecific antibody therapy in relapsed/refractory multiple myeloma (2026)

Research Square DOI OpenAlex
Social vulnerability index as an independent poor prognostic factor in patients with chronic hematological malignancies in Arkansas. (2026)

Journal of Clinical Oncology DOI OpenAlex
Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma. (2026)

Journal of Clinical Oncology DOI OpenAlex
Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma. (2026)

Journal of Clinical Oncology DOI OpenAlex
26-A-9693-ACC PREDICTION OF 1-YEAR MAJOR ADVERSE CARDIAC EVENTS IN CAR-T RECIPIENTS USING RISK SCORE MODELING: EXPANDED WHOLE-COHORT ANALYSIS (2026)

Journal of the American College of Cardiology DOI OpenAlex
26-A-11133-ACC CYTOKINE RELEASE SYNDROME-GUIDED RISK MODELS REDEFINE CARDIOTOXICITY SURVEILLANCE: OPTIMIZING DETECTION OF CANCER THERAPY-RELATED CARDIAC DYSFUNCTION AND ADVERSE CARDIOVASCULAR EVENTS AFTER CAR-T THERAPY (2026)

Journal of the American College of Cardiology DOI OpenAlex
26-CCC-15772-ACC A CASE OF ACUTE PROTRACTED NON-ISCHEMIC CARDIOMYOPATHY PRECEDING DEVELOPMENT OF BUNDLE BRANCH RE-ENTRANT TACHYCARDIA PRECIPITATED BY CYTOKINE RELEASE SYNDROME FOLLOWING CHIMERIC ANTIGEN T-CELL THERAPY (2026)

Journal of the American College of Cardiology DOI OpenAlex
Critical platelet shortages and a single Institution's experience with split platelet transfusions: Can you get by with just half a unit? (2025)

Blood DOI OpenAlex
Role of proliferation-related genes as predictive factors for adjuvant therapy in colon cancer. (2025)

Journal of Clinical Oncology DOI OpenAlex
Epidemiological and clinical trends in common hematological malignancies in Arkansas: Arkansas Central Cancer Registry (ACCR)-based study. (2025)

Journal of Clinical Oncology DOI OpenAlex
Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma (2025)

Blood Cancer Journal 39 citations DOI OpenAlex